Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elke M van Veen

Showing results (1-10 of 39) with videos related to

Pageof 4
Sort By:
Breast Care (Basel, Switzerland)|July 12, 2021
From <i>BRCA1</i> to Polygenic Risk Scores: Mutation-Associated Risks in Breast Cancer-Related GenesEmma R Woodward, Elke M van Veen, D Gareth Evans
Quantitative Imaging in Medicine and Surgery|December 3, 2020
Heritability of mammographic breast densityD Gareth Evans, Elke M van Veen, Anthony Howell, et al.
IEEE Journal of Biomedical and Health Informatics|November 17, 2022
A Novel Automated Approach to Mutation-Cancer Relation Extraction by Incorporating Heterogeneous KnowledgeJiarun Cao, Elke M van Veen, Niels Peek, et al.
Clinical Genetics|September 29, 2021
Dominant-negative pathogenic variant BRIP1 c.1045G>C is a high-risk allele for non-mucinous epithelial ovarian cancer: A case-control studyNicola Flaum, Elke M van Veen, Olivia Smith, et al.
European Journal of Human Genetics : EJHG|June 9, 2016
Sensitivity of BRCA1/2 testing in high-risk breast/ovarian/male breast cancer families: little contribution of comprehensive RNA/NGS panel testingHelen Byers, Yvonne Wallis, Elke M van Veen, et al.
International Journal of Cancer|August 30, 2021
The importance of ethnicity: Are breast cancer polygenic risk scores ready for women who are not of White European origin?D Gareth Evans, Elke M van Veen, Helen Byers, et al.
JAMA Oncology|January 19, 2018
Use of Single-Nucleotide Polymorphisms and Mammographic Density Plus Classic Risk Factors for Breast Cancer Risk PredictionElke M van Veen, Adam R Brentnall, Helen Byers, et al.
Journal of Medical Genetics|September 12, 2020
Constitutional de novo deletion CNV encompassing <i>REST</i> predisposes to diffuse hyperplastic perilobar nephroblastomatosis (HPLN)Zerin Hyder, Adele Fairclough, Mike Groom, et al.
International Journal of Cancer|June 29, 2019
A case-control evaluation of 143 single nucleotide polymorphisms for breast cancer risk stratification with classical factors and mammographic densityAdam R Brentnall, Elke M van Veen, Elaine F Harkness, et al.
Cancers|August 27, 2021
Gene Panel Testing for Breast Cancer Reveals Differential Effect of Prior <i>BRCA1/2</i> ProbabilityD Gareth Evans, Elke M van Veen, Emma R Woodward, et al.
Pageof 4

Showing results (1-10 of 39) with videos related to

Sort By:
Pageof 4
Breast Care (Basel, Switzerland)|July 12, 2021
From <i>BRCA1</i> to Polygenic Risk Scores: Mutation-Associated Risks in Breast Cancer-Related GenesEmma R Woodward, Elke M van Veen, D Gareth Evans
Quantitative Imaging in Medicine and Surgery|December 3, 2020
Heritability of mammographic breast densityD Gareth Evans, Elke M van Veen, Anthony Howell, et al.
IEEE Journal of Biomedical and Health Informatics|November 17, 2022
A Novel Automated Approach to Mutation-Cancer Relation Extraction by Incorporating Heterogeneous KnowledgeJiarun Cao, Elke M van Veen, Niels Peek, et al.
Clinical Genetics|September 29, 2021
Dominant-negative pathogenic variant BRIP1 c.1045G>C is a high-risk allele for non-mucinous epithelial ovarian cancer: A case-control studyNicola Flaum, Elke M van Veen, Olivia Smith, et al.
European Journal of Human Genetics : EJHG|June 9, 2016
Sensitivity of BRCA1/2 testing in high-risk breast/ovarian/male breast cancer families: little contribution of comprehensive RNA/NGS panel testingHelen Byers, Yvonne Wallis, Elke M van Veen, et al.
International Journal of Cancer|August 30, 2021
The importance of ethnicity: Are breast cancer polygenic risk scores ready for women who are not of White European origin?D Gareth Evans, Elke M van Veen, Helen Byers, et al.
JAMA Oncology|January 19, 2018
Use of Single-Nucleotide Polymorphisms and Mammographic Density Plus Classic Risk Factors for Breast Cancer Risk PredictionElke M van Veen, Adam R Brentnall, Helen Byers, et al.
Journal of Medical Genetics|September 12, 2020
Constitutional de novo deletion CNV encompassing <i>REST</i> predisposes to diffuse hyperplastic perilobar nephroblastomatosis (HPLN)Zerin Hyder, Adele Fairclough, Mike Groom, et al.
International Journal of Cancer|June 29, 2019
A case-control evaluation of 143 single nucleotide polymorphisms for breast cancer risk stratification with classical factors and mammographic densityAdam R Brentnall, Elke M van Veen, Elaine F Harkness, et al.
Cancers|August 27, 2021
Gene Panel Testing for Breast Cancer Reveals Differential Effect of Prior <i>BRCA1/2</i> ProbabilityD Gareth Evans, Elke M van Veen, Emma R Woodward, et al.
Pageof 4